Low preoperative prognostic nutritional index (PNI) has a significant impact on the completion of planned adjuvant chemotherapy (AC) following curative resection of stage II/III gastric cancer, a study has shown. Low PNI and incomplete AC confer an additive effect and lead to worse outcomes.
The rate of polypharmacy is high among patients with multiple myeloma, according to a study. However, comanagement with a pharmacist reduces the number of all medications, particularly those that are not related to myeloma.
MuGard and Caphosol do not appear to be more effective than standard topical therapy at reducing pain scores or increasing mucosal recovery in the treatment of chemotherapy-induced oral mucositis, a recent study has shown.
Isavuconazole, an extended spectrum mold-active triazole, is safe and effective as primary antifungal prophylaxis in patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome undergoing remission-induction chemotherapy, according to the results of a phase II study.
Patients with red blood cell transfusion dependence and an unfavourable molecular status suffer from worse relapse-free survival after haematopoietic cell transplantation for myelofibrosis, a recent study has shown.
The monoamine oxidase inhibitor phenelzine shows therapeutic potential in patients with biochemical recurrent castrate-sensitive prostate cancer, with manageable treatment-related toxicities, according to the results of a phase II trial.
Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.
Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.
At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.
“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.
Case presentation: The
patient is a 46-year-old Korean lady who first presented with aggravating
pleuritic chest pain characterised by a stabbing pain in the chest when
inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was
made from computed tomography (CT)-guided needle aspiration biopsy, and the
tumour was found to be epidermal growth factor receptor (EGFR)
mutation-positive (exon 19 deletion). Chest imaging revealed the presence of
left-sided pleural seeding nodules. The patient was treated with afatanib with
partial response as best response. Ten months after starting treatment, the
patient experienced disease progression.